Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Dendreon Corporation    

End-of-day quote. End-of-day quote  - 06/11
0.0325 USD   -4.41%
2015DJValeant Approved to Buy Dendreon Assets for $495 Million
2015 Drugmaker Valeant close to buying Salix - source
2015 VALEANT SECURES : Bloomberg
 SummaryChartsNewsCalendarCompanyFinancials 
Company
Dendreon Corp. is a biotechnology company, which focuses on discovery, development and commercialization of novel therapeutics that improves cancer treatment options for patients.The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular... 
More about the company
Latest news on DENDREON CORPORATION
2015DJValeant Approved to Buy Dendreon Assets for $495 Million
2015 Drugmaker Valeant close to buying Salix - source
2015 VALEANT SECURES FINANCING FOR POTENT : Bloomberg
2015DJEnergy Future Fights for Control of its Bankruptcy -- Week Ahead
2015 DENDREON : Valeant to buy Dendreon's prostate cancer vaccine Provenge
2014 DENDREON CORPORATION : A New Combined Approach to Cancer Immunotherapy is Needed
2014 DENDREON CORPORATION : Bankruptcies, Breakouts, and Busts; What's Happening in B..
2014DJMARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
2014DJMARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
2014DJMARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
More news
Sector news : Biotechnology & Medical Research - NEC
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart DENDREON CORPORATION
Duration : Period :
Dendreon Corporation Technical Analysis Chart | US24823Q1076 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Managers
NameTitle
Craig R. Jalbert President, Secretary, Treasurer & Director
William Monteith Executive Vice President-Technical Operations
Andrew S. Sandler Chief Medical Officer & Executive Vice President
April Falcone Head-Corporate Communications
Silvio Pacheco Chief Customer Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DENDREON CORPORATION-55.48%0
INCYTE CORPORATION-18.19%16 646
CELLTRION, INC.--.--%10 582
LONZA GROUP AG11.40%9 818
QUINTILES TRANSNATIONA..9.23%8 975
ALKERMES PLC-35.74%7 827
More Results